Three changes to the intervention content were determined from the different sources of data. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
29,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
BackgroundRecently published clinical studies suggest that blood-based biomarker tests (BBMTs) for Alzheimer's disease (AD) provide value, but in the U.S., neither public nor private payers currently cover these tests. 1 key finding →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The suppressed fraction rose with rarity: 7.4% of counties for breast, 61.3% for stomach, and 75.7% for cervix incidence. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There was a trend toward increased risk of being assaulted in the last year associated with being in a non-SCU facility. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We conducted a single-stage community-based study of dementia on all registered residents > or =65 years in age in a rural Chinese community. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Lower diagnosed dementia rates in MA compared to TM may exacerbate racial/ethnic disparities in diagnosed dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The COVID-19 pandemic and the social unrest pervading U.S. cities in response to the killings of George Floyd and other Black citizens at the hands of police are historically significant. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
36/100
Of 343 palliative care evaluations (for 322 unique patients), 38% were of patients who identified as African American/Black, 38% as White, 9% as Asian/Pacific Islander, and 15% as other races; 41% were of patients who identified as Hispanic/Latino (measured separately from race); 80% were of female patients; and the mean patient age was 88 years. 5 key findings →
Design: retrospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
36/100
Potentially inappropriate medication (PIM) use-defined as the use of high-risk medications that can increase the risk of adverse events such as physical, cognitive, and functional decline; delirium; hospitalizations; and mortality-remains a significant concern in older adults in the US.Numerous guidelines, including the American Geriatrics Society Beers Criteria 1 and the STOPP criteria, 2 define PIMs as medications for which the risk of adverse effects outweighs potential benefits or are inappropriate for specific populations or disease states, such dementia or kidney disease.PIM use may be particularly harmful in populations experiencing other health care disparities, as communities experiencing other consequences of health care inequity, including limited access to physicians or pharmacies, greater financial stress, and a higher comorbidity burden, may experience disproportionate effects from the adverse consequences of PIM use. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dispositional inward anger expression may increase susceptibility to the detrimental impacts of neighborhood disadvantage on cognitive health. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
One-third of hospitalizations were PPHs. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The effect of austerity and associated budgets are strong contenders,3Ruckert A Labonté R Health inequities in the age of austerity: the need for social protection policies. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These preliminary findings reveal white matter alterations associated with consensus MCI diagnosis and to socioeconomic differences in a clinical cohort of rural‐dwelling older adults. 5 key findings →
Participants: 69 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest differences in local cortical organization by neighborhood disadvantage, which also mediated the relationship between ADI and cognitive performance, providing a possible network‐based mechanism, explaining risk for cognitive decline and dementia associated with disadvantaged neighborhoods. 3 key findings →
Participants: 526 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest differences in local cortical organization by neighborhood disadvantage, which also mediated the relationship between ADI and cognitive performance, providing a possible network‐based mechanism, explaining risk for cognitive decline and dementia associated with disadvantaged neighborhoods. 3 key findings →
Participants: 526 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Neighborhood disadvantage in later life is associated with poorer cognition and increased vulnerability to dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mean performance on knowledge of dementia risk factor mitigation strategies significantly increased after viewing the animation (p < .001), with a clinically meaningful effect (mean change = 3.63). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
36/100
China has the world's highest dementia prevalence, disproportionately impacting rural areas. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
36/100
As the rates of Alzheimer's disease (AD) and AD and related dementias (ADRD) in the United States steadily rise, so too does the demand for informal caregiving. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
36/100
The findings revealed that Japanese physicians did not display support for euthanasia (2%) and assisted suicide (1%); however, the general public supported euthanasia (33%) and assisted suicide (34%). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
36/100
Dementia cases are projected to triple globally by 2050, largely driven by an aging population. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A longstanding body of public enquiries and research identifies people living with dementia experience systemic inequalities within hospital settings, concluding a focus on improving care cultures is required. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study investigated the current status and distribution of Alzheimer's disease (AD) among Mongolian and Han individuals who were at least 55 years old and living in rural areas of Inner Mongolia. 2 key findings →
Participants: 9,266 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Accessibility to food stores offering nutritious and affordable options is critical to ensure urban residents lead healthy lives. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Greater adherence to MedDiet and frequency of consumption of some foods were associated with better scores in several CF tests in elderly individuals with high risk of MS living in a rural community. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 926 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Mental Health Treatment Among Nursing Home Residents With Alzheimer's Disease and Related Dementias
- Predictors of survival in patients with Parkinson disease
- Frequency and clinical determinants of dementia after ischemic stroke
- Real-World Outcomes of a Telephone-Based Virtual Cognitive Rehabilitation Therapy Program: A Retrospective Cohort Analysis
- Pharmacotherapy for Depression in Long-Term Care: A Real-World EHR Study
- Global, Regional and Country-Specific Burden of Dementia Associated with Depression Across the Life-course
- Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK
- Association of neighborhood socioeconomic disadvantage and cognitive impairment
- Sex differences and the role of education in cognitive ageing: analysis of two UK-based prospective cohort studies
- Association between apolipoprotein E genotype and Alzheimer disease in African American subjects
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,380 records, built mostly from automated pulls of Europe PMC (63.3% of the library) and OpenAlex (17.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →